BioPharmSignal logoBioPharmSignal

Biotech News

Olema Oncology Appoints Jason O’Byrne as Chief Financial Officer

Olema Pharmaceuticals, Inc. (OLMA)Olema Pharmaceuticals, Inc.Company update

SAN FRANCISCO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced the

Related news

OLMAOlema Pharmaceuticals, Inc.2026-08-10 20:01 EST

Olema Oncology Reports Second Quarter 2026 Financial and Operating Results

OLMAOlema Pharmaceuticals, Inc.2026-08-04 20:30 EST

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KYMRKymera2026-07-27 20:01 EST

Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer

CHRSCoherus BioSciences, Inc.2026-08-05 20:28 EST

Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update

KURAKura Oncology2026-08-05 11:30 EST

Kura Oncology to Report Second Quarter Financial Results

CHRSCoherus BioSciences, Inc.2026-07-22 17:36 EST

Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026

GERNGeron2026-07-13 12:00 EST

Geron Announces Appointment of Chinmaya Rath as Chief Business Officer

REPLReplimune Group2026-08-14 12:00 EST

Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update

GNLXGenelux2026-08-13 20:20 EST

Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates

KURAKura Oncology2026-08-12 20:02 EST

Kura Oncology Reports Second Quarter 2026 Financial Results

View all latest news

Olema Pharmaceuticals, Inc.

Endocrine-Driven Cancer Company Olema Oncology develops targeted therapies based on estrogen receptor biology, nuclear receptors, and resistance mechanisms in breast cancer. Palazestrant Palazestrant is an oral complete estrogen receptor antagonist being studied as monotherapy and in combinations for ER-positive, HER2-negative breast...

Recent company news

OLMAOlema Pharmaceuticals, Inc.2026-08-13 11:00 EST

Olema Oncology Appoints Jason O’Byrne as Chief Financial Officer

OLMAOlema Pharmaceuticals, Inc.2026-08-10 20:01 EST

Olema Oncology Reports Second Quarter 2026 Financial and Operating Results

OLMAOlema Pharmaceuticals, Inc.2026-08-04 20:30 EST

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

OLMAOlema Pharmaceuticals, Inc.2026-07-02 20:30 EST

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

OLMAOlema Pharmaceuticals, Inc.2026-06-02 20:30 EST

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
10.77 USD
Market cap
933.74M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States